Chronic kidney disease (CKD) is a public health problem affecting the patients to suffer, reduce their quality of life, and loss of many expenses. CKD in the early stages is usually without abnormal symptoms. Most patients are unaware that they have kidney disease, usually diagnosed when the disease has severely progressed. When the disease progresses into the end-stage of chronic renal failure due to kidneys are unable to sufficiency support the excretion of waste products and conditions of the
Conditions
Interventions
Cymbopogon citratus Stapf. water extract capsule dose 900 mg/day or 2 capsules, orally once a day before lunch for 90 consecutive days. ,placebo capsules content of starch- which were the same pattern
Cymbopogon citratus Stapf. extract ,Control
Sponsors
THAI TRADITIONALMEDICALKNOWLEDGE FUND, Thailand
Eligibility
Sex/Gender
All
Age
35 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Male or female participants aged between 35- 85 years 2. Participants with stage 3B chronic kidney disease and had an eGFR between 30-44 ml / min / 173m2.
Exclusion criteria
Exclusion criteria: 1. Participants with cancer of all types from the first stage onwards 2. Participants with heart disease or heart abnormality in all cases 3. Participants with liver disease, hepatitis, cirrhosis, fatty liver 4. Participants with diabetic nephropathy 5. Participants with chronic infection and are undergoing treatment for an infection 6. Participants with alcoholism 7. Participants with autoimmune disease, SLE, rheumatoid arthritis and are taking corticosteroids, immunosuppressants or immunosuppressive agents 8. Participants with during of pregnant or breastfeeding 9. Participants with history of lemongrass allergy 10. Participants with prolonged obstruction of the urinary tract, such as enlarged prostate and kidney stones 11. Participants with overactive bladder (OAB) 12. Participants currently participating in another study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| urinary angiotensinogen pre-post treatment 90 day Urine ,TGF-beta pre-post treatment (90 day) Urine,Nitric oxide (NO) pre post treatment (90 day) Urine,interleukin 6 (IL-6) pre-post treatment (90 day) Blood,Ultrasound Doppler for Resistive index (RRI) pre-post treatment (90 day) Ultrasonography, BUN, Creatinine, Electrolyte, eGFR, CBC, LFT Baseline, monthly for 3 time Blood,FBS, Cystatin C, hs-CRP, Phosphorus, Calcium, Magnesium, uric acid pre-post treatment (90 day) Blood,Urine examination (UA) Baseline, monthly for 3 time Urine,urine 24 hr. pre-post treatment and day 10 in periods study Urine | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life pre-post treatment (90 day) Kidney Disease Quality of Life Short Form - KDQOL SFTM version 1.3 | — |
Countries
Thailand
Contacts
Public ContactKusuma Sriyakul
Integrative Medicine Chulabhorn International College of Medicine Thammasat University
Outcome results
None listed